title: Limaprost alfadex and nonsteroidal anti-inflammatory drugs for sciatica due to lumbar spinal stenosis.
abstract: OBJECTIVE
  Limaprost, a prostaglandin E1 analog, has vasodilatory properties and increases blood flow of the nerve root. However, it has not been clarified whether limaprost affects pain sensation associated with radiculopathy due to lumbar spinal stenosis (LSS). The aim of this study was to compare the efficacy of oral limaprost with nonsteroidal anti-inflammatory drugs (NSAIDs) for radiculopathy.
  
  
  METHODS
  We performed a multicenter prospective randomized trial. Patients with LSS who had radicular-type neurologic intermittent claudication assessed based on a self-reported diagnostic support tool were randomized into three treatment groups. Limaprost, NSAIDs, or limaprost plus NSAIDs were administered orally for 6 weeks. Leg pain, low back pain (LBP) and the associated symptoms were assessed by a numerical rating scale (NRS) both at rest and on movement as well as the Roland-Morris Disability Questionnaire (RDQ) and Short Form (SF)-36.
  
  
  RESULTS
  Sixty-one patients were enrolled in the study. Each treatment finally reduced radicular pain, and the improvement was prominent in a combination treatment. There were no significant differences in radicular pain among three groups at final follow-up. LBP was not influenced by limaprost, and a significant reduction of LBP and RDQ was confirmed in a combination treatment compared with limaprost. Physical function of the SF-36 subscales after a combination treatment showed a marked alleviation compared with NSAIDs.
  
  
  CONCLUSIONS
  These obtained findings suggest that the effects of limaprost seem to be limited to radicular pain, not for LBP. Overall, a combination treatment might be more effective in the management of radiculopathy induced by LSS than monotherapy with either agent.
authors.affiliation: Department of Orthopaedic Surgery, School of Medicine, Fukushima Medical University, Fukushima, Fukushima, Japan. aonda777@air.ocn.ne.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Onda
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Shoji
authors.initials: S
authors.lastname: Yabuki
authors.forename: Koji
authors.initials: K
authors.lastname: Otani
authors.forename: Takuya
authors.initials: T
authors.lastname: Nikaido
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Watanabe
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Konno
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D004185:Disability Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012585:Sciatica / Q000188:drug therapy* / Q000209:etiology*; D013130:Spinal Stenosis / Q000150:complications*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D047391:alpha-Cyclodextrins / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D047391:alpha-Cyclodextrins; C525749:limaprost-alfadex; D000527:Alprostadil